Premium
Impact of cyclosporine‐A concentration in T‐cell replete haploidentical allogeneic stem cell transplantation
Author(s) -
Yang Xiaofei,
Yang Shuo,
Sun Aining,
Qiu Huiying,
Tang Xiaowen,
Han Yue,
Wu Depei
Publication year - 2018
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.13220
Subject(s) - medicine , cumulative incidence , hematopoietic stem cell transplantation , gastroenterology , transplantation , odds ratio , incidence (geometry) , graft versus host disease , immunology , physics , optics
This paper aims to study whether cyclosporine‐A ( CSA ) levels have an impact on the clinical outcome of patients with T‐cell replete haploidentical allogeneic hematopoietic stem cell transplantation (allo‐ HSCT ). We analyzed 140 consecutive patients who had been given T‐cell replete haploidentical allo‐ HSCT in our institute to assess the effect of CSA concentration in the early stages of allo‐ HSCT on clinical outcomes, such as hematopoietic recovery, acute graft vs host disease ( aGVHD ), infection, disease‐free survival ( DFS ), and overall survival ( OS ). The median concentrations of CSA in the blood in the 1st, 2nd, 3rd, and 4th week after allo‐ HSCT were 218, 235, 263, and 270 ng/mL, respectively. Additionally, 46%, 40%, 27%, and 18% of the patients had CSA blood levels below 200 ng/mL during those weeks. In total, 39 patients developed aGVHD (grade II ‐ IV ), for a cumulative incidence of 27.8%, at a median of 32 days. Patients having a low CSA concentration (below 200 ng/mL) in the 3rd week had a higher cumulative incidence of grade II ‐ IV aGVHD ( P = .02). In addition, multivariate logistic regression analysis showed that low CSA concentration (below 200 ng/mL) in the 3rd week was an independent risk factor of grade II ‐ IV aGVHD ( P = .02; odds ratio = 2.66; 95% CI , 1.15‐6.17). However, CSA levels during the first 4 weeks did not have a significant impact on the patients’ hematopoietic recovery, infection, DFS , and OS . Our data indicated that adequate management of CSA levels during the peri‐engraftment period might improve clinical outcomes for those with T‐cell replete haploidentical allo‐HSCT.